CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 6.48: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.95%
Annual Rate
CNY 0.60Paid annual
Payout Ratio
391.7%High
Payback Period
58.9 yr
Last Ex-Dividend
Jun 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.52BCNY376.74M · vs all stocks (USD)
Revenue (TTM)
1.15BCNY171.22M · vs all stocks (USD)
Profit Margin
-1.86%vs Biotechnology peers
52-Week Change
-0.03%vs all stocks
Market Capitalization
2.52BCNY376.74M · vs all stocks (USD)
Enterprise Value
1.45BCNY216.15M · vs all stocks (USD)
Price to Sales (TTM)
2.20xvs Biotechnology peers
Price to Book (MRQ)
1.27xvs Biotechnology peers
Enterprise to Revenue
1.26xvs Biotechnology peers
Enterprise to EBITDA
-33.02xvs Biotechnology peers
Gross Margin
20.82%vs Biotechnology peers
Profit Margin
-1.86%vs Biotechnology peers
Operating Margin
-0.86%vs Biotechnology peers
Return on Assets (TTM)
-1.72%vs Biotechnology peers
Return on Equity (TTM)
-1.08%vs Biotechnology peers
Revenue (TTM)
1.15BCNY171.22M · vs all stocks (USD)
Revenue per Share (TTM)
13.37CNYUpdated Sep 21, 2026Quarterly Revenue Growth
7.20%vs Biotechnology peers
Gross Profit (TTM)
226.40MCNY33.78M · vs all stocks (USD)
EBITDA (TTM)
-43.87MCNY-6.55M · vs all stocks (USD)
Net Income (TTM)
-21.36MCNY-3.19M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
42.92%vs Biotechnology peers
Operating Cash Flow (TTM)
-48.58MCNY-7.25M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-131.75MCNY-19.66M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.6000CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
1.95%vs all stocks
Payout Ratio
391.67%vs Biotechnology peers
Revenue
1.08BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
880.13MCNYFY2025 · Dec 31, 2025Gross Profit
203.57MCNYFY2025 · Dec 31, 2025Operating Income
-41.95MCNY-6.26M · vs all stocks (USD)
Pre-tax Income
-33.67MCNYFY2025 · Dec 31, 2025Income Tax Expense
-10.72MCNYFY2025 · Dec 31, 2025Net Income
-22.95MCNYFY2025 · Dec 31, 2025EBIT
-32.76MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-4.95MCNYFY2025 · Dec 31, 2025Research & Development
67.01MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
23.11MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.27MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.01MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
904.42KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.2600CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.2600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
88.26MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
88.26MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-22.95MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-31.20MCNYFY2025 · Dec 31, 2025Free Cash Flow
-127.16MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
545.52MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-22.95MCNYFY2025 · Dec 31, 2025Other Non-cash Items
5.78MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
669.66KCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-14.70MCNYFY2025 · Dec 31, 2025Capital Expenditures
-95.96MCNYFY2025 · Dec 31, 2025Purchase of Investments
-4.15BCNYFY2025 · Dec 31, 2025Sale of Investments
3.91BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-334.33MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
44.47MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
0.00CNYFY2025 · Dec 31, 2025Common Dividends Paid
-19.98MCNYFY2025 · Dec 31, 2025Other Financing Charges
-25.95MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.46MCNYFY2025 · Dec 31, 2025Shares Outstanding
86.17MSharesUpdated Sep 21, 2026Float Shares
39.55MSharesUpdated Sep 21, 2026% Held by Insiders
53.74%vs all stocks
% Held by Institutions
5.35%vs all stocks
Total Cash (MRQ)
1.07BCNY159.26M · vs all stocks (USD)
Total Cash per Share (MRQ)
12.77CNYUpdated Sep 21, 2026Total Debt (MRQ)
67.85MCNY10.12M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0351xvs Biotechnology peers
Current Ratio (MRQ)
5.77xvs Biotechnology peers
Book Value per Share (MRQ)
23.15CNYUpdated Sep 21, 2026Total Assets
2.30BCNY343.57M · vs all stocks (USD)
Total Current Assets
1.87BCNYFY2025 · Dec 31, 2025Total Liabilities
296.56MCNYFY2025 · Dec 31, 2025Total Non-current Assets
433.24MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
11.35MCNYFY2025 · Dec 31, 2025Total Current Liabilities
285.21MCNYFY2025 · Dec 31, 2025Cash
542.70MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.82MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
545.52MCNYFY2025 · Dec 31, 2025Other Short-term Investments
803.59MCNYFY2025 · Dec 31, 2025Accounts Receivable
362.85MCNYFY2025 · Dec 31, 2025Inventory
128.47MCNYFY2025 · Dec 31, 2025Accounts Payable
96.43MCNYFY2025 · Dec 31, 2025Short-term Debt
49.05MCNYFY2025 · Dec 31, 2025Other Current Liabilities
7.12MCNYFY2025 · Dec 31, 2025Long-term Debt
4.59MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
4.20MCNYFY2025 · Dec 31, 2025Common Stock (Book)
86.67MCNYFY2025 · Dec 31, 2025Retained Earnings
197.00MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.01BCNY299.31M · vs all stocks (USD)
Treasury Stock
37.76MCNYFY2025 · Dec 31, 202552-Week Low
23.89CNYUpdated Sep 21, 202652-Week High
36.42CNYUpdated Sep 21, 202652-Week Change
-0.03%vs all stocks
50-Day MA
27.85CNYUpdated Sep 21, 2026200-Day MA
29.87CNYUpdated Sep 21, 2026Avg 10-Day Volume
1.47MSharesUpdated Sep 21, 2026Avg 30-Day Volume
2.49MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-0.2500CNYUpdated Sep 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.48: safe zoneNotable
Altman Z-Score: 6.48
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Shengda Bio-Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Rezolute, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Huasun Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Orthofix Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Fennec Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
G2GBio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Edan Instruments Inc.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Yamaichi Electronics Co., Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Guangdong Silver Age Sci & Tech Co. Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated